logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

News

boto imprimir
Date: 03/10/2017

IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients


Researchers of the Chromatin and Disease Group from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona have identified a distinctive epigenetic event in immune cells that differentiate in the tumoral microenvironment and make them tolerant to cancer cells.

 

The tumoral microenvironment subverts immune cell function

 

In the past few years, there have been increasing evidences that inflammatory factors released in the tumor microenvironment are able to redirect the differentiation of immune-promoting dendritic cells to myeloid-derived suppressor cells, which decrease the ability of the cancer patient immune system to fight against the cancer cells. A number of studies have identifed factors, suchs as prostaglandin E2, that have the capacity to subvert the immunity of the cancer patients.

 

A key regulator of myeloid derived suppressor cells and the possibility of reverting its effects on immune fucntion

 

In this study, published today in the journal Cell Reports, and led by Dr. Esteban Ballestar (IDIBELL), the comparison of the epigenetic profiles between dendritic cells and myeloid-derived suppressor cells has allowed them to identify the existence of specific epigenetic alterations that associated with the development of myeloid-derived suppressor cells as a result of exposure to prostaglandin E2.

 

The team has been able to prove that such epigenetic alterations are associated with the increased levels of an enzyme, namely DNA methyltransferase 3A (DNMT3A), which is responsible for the acquisition of the suppressive properties of these cells that develop in the tumoral microenvironment. Inhibition of DNMT3A resulted in erasing the suppressive properties of these cells.

 

One of the most relevant findings of this study is that the observed epigenetic features of these cells are also present in myeloid-derived suppressor cells isolated from patients with ovarian carcinoma. Given the interest in developing drugs against DNA methyltransferases, the results by this team open up potential therapeutic opportunities for further exploration.

 

This study has been completed with the participation of researchers and clinicians at the University of Pittsburg, the University of California, Irvine as well as the Fundación MD Anderson International in Madrid.

 

Article citation

 

Rodríguez-Ubreva, J., Català-Moll, F., Obermajer, N., Álvarez-Errico, D., Ramirez, R.N., Company, C., Vento-Tormo, R., Moreno-Bueno, G., Edwards, R.P., Mortazavi, A., Kalinski, P., and Ballestar, E. (2017) Prostaglandin E2 leads to the acquisition of DNMT3A-dependent tolerogenic functions in human myeloid-derived suppressor cells. Cell Reports.


More information:

 Prostaglandin E2 leads to the acquisition of DNMT3A-dependent tolerogenic functions in human myeloid-derived suppressor cells.





Share/Bookmark
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell